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et al., 2002). No mutations in p38α 
have been reported in primary tumors; 
the presence of three other p38 MAPK 
genes could compensate for any par-
tial loss of function of p38α.
The successful creation of a tumor 
requires that the apoptotic and antip-
roliferative effects of p38 MAPK must 
be suppressed. Dolado et al. propose 
that one mechanism employed by 
tumor cells to overcome the tumor-
suppressive function of p38 MAPK is to 
uncouple the production of ROS from 
p38 MAPK activation. The increased 
expression of GSTm proteins (Gstm1 
and GSTm2) observed in tumor cells 
may serve this function. Dolado et 
al. show that reduced expression of 
GSTm2 in MCF7 breast cancer cells 
increased p38 MAPK activity and 
apoptosis, whereas forced overex-
pression of GSTm2 further potentiated 
the transformed phenotype. Since 
GSTm proteins can inhibit the ASK1/
p38 pathway, these data are compel-
ling. However, it is unclear if the over-
expression of GSTm proteins in these 
cancer cells is a cause of or a result of 
transformation or if the increased levels 
reflect responses to tumor treatment or 
passage in tissue culture. Neverthe-
less, proteins that serve as sensors for 
ROS levels (e.g., GSTm1/2) and other 
proteins that attenuate the p38 MAPK 
pathway (e.g., WIP1) represent candi-
date drug targets for the design of new 
therapies for cancer.
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Inherited breast cancer is associated with germline mutations in ten different genes in pathways 
critical to genomic integrity. BRCA1 and BRCA2 mutations confer very high risks of breast and 
ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare 
cancer syndromes. Mutations in CHEK2, ATM, NBS1, RAD50, BRIP1, and PALB2 are associated 
with doubling of breast cancer risks. In addition, biallelic mutations in BRCA2, BRIP1, and PALB2 
cause Fanconi anemia. The convergence of these genes in a shared role reveals underlying biology 
of these illnesses and suggests still other breast cancer genes.Fanconi anemia (FA) is a recessive syn-
drome characterized by chromosomal 
instability, congenital malformations, 
progressive bone marrow failure, and 
hypersensitivity to DNA crosslink-
ing agents (Taniguchi and D’Andrea, 
2006). The genes responsible for 11 of 
the 12 FA complementation groups (A, 
B, C, D1, D2, E, F, G, I, J, L, and M) have 
been identified. Eight FA proteins form 
a complex that activates FANCD2 via 
monoubiquitination (Figure 1). Monou-biquitinated FANCD2 then translocates 
to damage-induced nuclear foci con-
taining BRCA1, BRCA2, and RAD51, 
allowing recognition and repair of 
DNA interstrand crosslinks. Biallelic 
mutations in BRCA2 cause a rare and 
highly cancer-prone form of FA (FA-D1) 
(Howlett et al., 2002), and biallelic muta-
tions in the DNA helicase BRIP1 cause 
FA-J (Litman et al., 2005). BRCA2 and 
BRIP1 function downstream of the 
FANCD2 activation step.Cancer Cell 11Biallelic mutations in PALB2, the 
“partner and localizer of BRCA2,” are 
responsible for a new FA complemen-
tation group, FA-N (Xia et al., 2006a; 
Reid et al., 2006). PALB2 was originally 
identified in a screen for proteins pres-
ent in complexes containing BRCA2 
(Xia et al., 2006b). PALB2 binds to the 
extreme N terminus of BRCA2 and sta-
bilizes BRCA2 in key nuclear structures, 
allowing it to function in DNA repair and 
at the S phase checkpoint. Decrease of , February 2007 ©2007 Elsevier Inc. 103
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fanconi Anemia
A complex of eight Fanconi proteins (A, B, C, E, F, G, L, and M) activates FANCD2 via monoubiq-
uitination, allowing FANCD2 to translocate to damage-induced nuclear foci that contain BRCA1, 
BRCA2, and RAD51. DNA damage activates ATM and CHEK2, which in turn activate BRCA1 by 
phosphorylation. PTEN binds to the Rad51 promoter and may regulate its transcription (Shen et 
al., 2007). Proteins indicated in red carry germline mutations that predispose to breast cancer. 
The numbers indicate different breast-cancer-associated mutations identified thus far in each 
gene. A germline variant in the promoter of Rad51 (blue) may modify breast cancer risk in BRCA2 
mutation carriers (Levy-Lahad et al., 2001).PALB2 expression in HeLa cells by siR-
NAs leads to mitomycin C sensitivity, 
which causes interstrand crosslinking 
and eventually double-strand breaks. 
Mitomycin C sensitivity is a hallmark of 
Fanconi anemia.
Reid and colleagues identified bial-
lelic protein-truncating mutations in 
PALB2 in 7 of 82 individuals with FA 
not due to known genes (Reid et al., 
2006). In a lymphoblastoid line from 
one patient with two such muta-
tions, transfection of wild-type PALB2 
reversed sensitivity to mitomycin C. All 
seven individuals with FA-N developed 
cancer as children; six of the seven 
patients died before age 4.
Xia and colleagues evaluated one FA 
patient with normal monoubiquitination 
of FANCD2 and wild-type sequences 
of BRCA2 and BRIP1 (Xia et al., 2006a). 
This patient carried a premature trun-
cation in exon 4 of PALB2 inherited 
from the mother and a complete dele-
tion of PALB2 inherited from the father. 
A subline of the patient’s lymphoblasts 
developed MMC resistance, that 
is, became a phenotypic revertant. 
Genomic analysis of this line revealed 
an Alu-mediated deletion of exon 4 
that contains the premature truncation, 104 Cancer Cell 11, February 2007 ©200creating an in-frame mRNA with exon 3 
spliced to exon 5.
The cellular and cancer pheno-
types of patients with biallelic BRCA2 
mutations and of patients with biallelic 
PALB2 mutations are quite similar. Het-
erozygosity for mutations in BRCA2 are 
associated with very high risk of breast 
cancer. Is it possible that heterozygos-
ity for mutations in PALB2 also increase 
risk of breast cancer?
Rahman and colleagues sequenced 
the 13 coding exons of PALB2 in DNA 
from 923 familial breast cancer patients 
with wild-type sequences at BRCA1 
and BRCA2 (Rahman et al., 2006). 
Five different truncating mutations of 
PALB2 were identified in ten patients 
(1% of the series; two of the five muta-
tions were also observed in the FA-N 
families described above). No truncat-
ing mutations of PALB2 appeared in 
1084 control individuals. The relative 
risk of breast cancer associated with 
PALB2 was estimated at 2.3 (3.0 for 
women younger than 50 years and 1.9 
for women older than 50 years).
Erkko and colleagues sequenced 
PALB2 in DNA from 113 families from 
northern Finland with breast and ovar-
ian cancer, identifying a premature 7 Elsevier Inc.truncation in three families (Erkko et 
al., 2007). Further genotyping revealed 
the allele in 18 of 1918 (0.9%) breast 
cancer cases not selected for family 
history from the northern Finland pop-
ulation and 6 of 2501 (0.2%) controls, 
consistent with a 2- to 4-fold increased 
risk to mutation carriers.
PALB2 is a new addition to the 
growing list of genes associated with 
approximately 2-fold increased risk 
of breast cancer. CHEK2 was the first 
gene of this type described. Truncating 
allele 1100delC of CHEK2 was identi-
fied through a combined linkage and 
candidate gene approach in a single 
severely affected breast cancer fam-
ily (Meijers-Heijboer et al., 2002). This 
allele has a frequency of 0.002–0.005 in 
northern Europe populations and con-
fers an approximately 2-fold increased 
risk of breast cancer. Other CHEK2 
mutations have been subsequently 
associated with similarly increased risk 
of breast cancer (Walsh et al., 2006). In 
NBS1, a rare protein-truncating allele 
first identified in Polish breast cancer 
patients is associated with approxi-
mately 2-fold increased risk. Rare 
mutations of BRIP1 (FA-J) were also 
identified in breast cancer families 
(Seal et al., 2006). Heterozygous car-
riers of ATM mutations have long been 
suspected of having increased risk of 
breast cancer. Recent comprehen-
sive sequencing of ATM in 434 familial 
breast cancer patients revealed seven 
protein-truncating alleles, two splice 
mutations, and two missense alleles 
(one of which appeared in two families) 
experimentally verified to affect ATM 
function. In contrast, only two ATM 
sequence variants were found in 521 
controls (Renwick et al., 2006). Finally, 
a protein-truncating allele of RAD50 
identified in northern Finland conferred 
an approximate 4-fold increased risk of 
breast cancer (Heikkinen et al., 2006). 
In each of these genes, more mutations 
are likely to be found: more populations 
will be analyzed, genomic rearrange-
ments will be evaluated, and a larger 
subset of missense alterations will be 
validated by functional assays.
These ten genes share two impor-
tant features in their impact on breast 
cancer. (1) A single deleterious muta-
tion in any one of them is sufficient to 
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risk. (2) There are many deleterious 
mutations, and each mutation is indi-
vidually rare. That is, for none of these 
genes (individually or in combination) 
does increased risk of breast cancer 
result from additive effects of mul-
tiple common alleles, each of small 
influence. Inherited breast cancer 
is highly genetically heterogeneous 
with respect to both loci and alleles 
involved. All evidence to date is that 
the model that best reflects this het-
erogeneity is not a “common disease-
common allele” model, but instead 
a “common disease-multiple rare 
alleles” model.
The ten known genes for inherited 
breast cancer function in a pathway 
whose role is to preserve genomic 
integrity. Roughly 50% of familial 
breast cancer remains unresolved 
by any of these genes. Clearly other 
genes in this pathway are worthy of 
in-depth genomic analysis in unre-
solved families. Furthermore, in thus 
far unrecognized members of this 
pathway, mutations may also be asso-
ciated with inherited breast cancer.Wilms tumor (WT) is a childhood 
embryonal cancer of the kidney. Unlike 
most tumors, Wilms tumors gener-
ally exhibit few, if any, chromosomal 
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